Medarex's MDX-1100 meets Phase II endpoint

Medarex Inc. (NASDAQ:MEDX) said top-line data from a Phase II trial showed that 10 mg/kg MDX-1100 every two weeks met the primary endpoint of a significant improvement in ACR20 at week 12 vs. placebo ...